Covaris Installed Instrument Base Reaches 500 Units

WOBURN, MA—November 28, 2008—Covaris Incorporated today announced that during the summer of 2008, the company celebrated the shipment of its 500th instrument unit and continued another successful year throughout 2008. To accommodate this rapid business growth, Covaris is both strengthening its sales and marketing organization as well as implementing a 50% expansion of its main facility.

The Covaris business was built upon the proprietary and patented AFA™ (Adaptive Focused Acoustics) technology. The AFA technology has the ability of impart both thermal and non-contact control of application processes, which, in many cases, could not be obtained prior to the development of AFA technology. This unique and sustainable competitive advantage enables Covaris to develop a broad range of applications in Genomics, Proteomics and Drug Discovery research.

“There has been an increased systematic acceptance of our technology over the past few years. We are pleased to see our sample preparation tools gaining market acceptance and incorporated into daily research investigations throughout research institutions and pharmaceutical companies, such as the Broad Institute, GlaxoSmithKline and Merck, ” said Jim Laugharn, President and CEO of Covaris, “with the help of our customers, we have developed and optimized solutions for various key applications, such as DNA shearing for next-gen sequencing, RNA extraction for gene expression profiling, analyte and small molecule extraction from difficult tissue samples, compound formulation, and ADME/Tox.”

“I’m truly impressed with the solid technology and product platform Covaris has developed and its experienced team of people with well-balanced knowledge ranging from acoustic physics, mechanical engineering to biophysics and molecular biology,” commented Jennifer Wu, the newly hired Director of Marketing, “I’m honored and excited to join Covaris to further expedite marketing programs, market development and customer experience enhancement.”

About Covaris, Inc.
Covaris, Inc. is a rapidly growing life science instrument company.  Its proprietary instrument platform, based on patented Adaptive Focused Acoustic (AFA) technology brings unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise, and accurate energy to biological and chemical samples. The process is non-contact, isothermal, and rapid.  Leading pharmaceutical and biotechnology companies worldwide are using Covaris instruments for RNA extraction, Compound Dissolution, Drug Metabolism tissue extraction, and much more. Information about Covaris is available at https://www.covaris.com.

Contact:
Covaris, Inc.
Jim Laugharn, President & CEO
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
Tel: +1 781-932-3959
Fax: +1 781-932-8705
e-mail: info@covaris.com
web: www.covaris.com

In Sequence Magazine Interviews Covaris President About Benefits of ABI Partnership

WOBURN, MA—November 27, 2007—Today the editors of In Sequence, the Inside Read on Genome Sequencing, published an article based on an interview with Jim Laugharn, President and CEO of Covaris, Incorporated. The article focused on the potential of the recent supply and distribution agreement signed between Applied Biosystems and Covaris.  A key part of the agreement is that Applied Biosystems will sell and support Covaris™ S2 sample preparation instrument system for use with Applied Biosystems’ recently launched next-generation genetic analysis platform, the SOLiD™ System.

The full text of the In Sequence article follows below.

ABI Tested Covaris DNA Shearing Instrument for 9 Months Prior to Deal
ABI tested and evaluated Covaris’ S2 sample prep system for about nine month prior to deciding to sell the instrument along with its SOLiD sequencer, according to an ABI spokesperson (see In Sequence 11/13/2007).

“It was determined that the [Covaris’] Adaptive Focused Acoustic technology would bring speed and efficiency to biological and chemical sample preparation that would help SOLiD System customers take advantage of emerging applications for next-gen sequencing and help ensure they receive quality data,” the spokesperson told In Sequence by e-mail.

Scientists at Agencourt Personal Genomics used Covaris’ instrument even prior to APG’s acquisition by ABI, Covaris president and CEO Jim Laugharn told In Sequence by e-mail.

The list price of the Covaris S2 instrument, which is included in ABI’s $600,000 SOLiD system, is $40,000.

Customers of other sequencing platforms can also buy an instrument directly from Covaris and use it for DNA shearing purposes, according to Laugharn.

The Covaris S2 instrument shears genomic DNA into short fragments with uniform and consistent size fractions, with a target range between 100 and 200 base pairs for SOLiD fragment libraries.

The instrument can also be used for lysing cells and tissues, and to micronize particulates and solvate molecules for chemical samples, such as nanoparticles, according to Laugharn.

Like sonicators, the Covaris technology uses acoustic energy, but it precisely controls and efficiently delivers mechanical energy in a non-contact, isothermal, and rapid manner, he said. The technology is a combination of diagnostic imaging ultrasound signal processing and high intensity, therapeutic ultrasound technologies.

http://www.in-sequence.com/issues/1_45/short_reads/143610-1.html

About Covaris, Inc.
Covaris, Inc. is a rapidly growing life science instrument company. Its proprietary instrument platform, based on patented Adaptive Focused Acoustic (AFA) technology brings unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise, and accurate energy to biological and chemical samples. The process is non-contact, isothermal, and rapid. Leading pharmaceutical and biotechnology companies worldwide are using Covaris instruments for RNA extraction, Compound Dissolution, Drug Metabolism tissue extraction, and much more. Information about Covaris is available at https://www.covaris.com.

Contact:
Covaris, Inc.
Jim Laugharn, President & CEO
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
Tel: +1 781-932-3959
Fax: +1 781-932-8705
e-mail: info@covaris.com
web: www.covaris.com

Covaris Announces Supply and Distribution Agreement with Applied Biosystems

WOBURN, MA —November 13, 2007 —Covaris Incorporated today announced that it has entered into a supply and distribution agreement with Applied Biosystems.  As part of the agreement, Applied Biosystems will sell and support Covaris™ S2 sample preparation instrument system for use with Applied Biosystems’ recently launched next-generation genetic analysis platform, the SOLiD™ System.

The Covaris sample preparation technology, which is based on its patented Adaptive Focused Acoustic™ technology, brings speed and efficiency to biological and chemical sample preparation.

The Covaris technology accelerates next-generation DNA sequencing sample preparation.  The technology involves bead handling, and fragment and mate-pair library compilation to accelerate bead reaction and DNA shearing, which enables the generation of up to 35 base pairs of sequence data.

“Our relationship with Covaris has helped us to develop the most robust, accurate, and highest-throughput genetic analysis platform in the marketplace today to help our customers take advantage of the emerging applications for next-generation DNA sequencing,” said Kim Caple, vice president and general manager for Applied Biosystems’ next-generation sequencing business.  “Covaris provides a reliable system for biological sample preparation that is an integral part of the SOLiD System workflow.”

According to Jim Laugharn, President and CEO of Covaris, “This agreement reflects the fundamental benefits the Covaris technology has for biological and chemical sample processing.  For example, this versatile instrument can be used for both high intensity shearing of genomic DNA with one sample and for controlled, gentle mixing of enzymatic reaction beads in the next sample.

“Partnering with a life sciences industry leader such as Applied Biosystems enables Covaris to continually bring advanced tools to the market,” said Laugharn.

About Covaris, Inc.
Covaris, Inc. is a rapidly growing life science instrument company. Its proprietary instrument platform, based on patented Adaptive Focused Acoustic (AFA) technology brings unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise, and accurate energy to biological and chemical samples. The process is non-contact, isothermal, and rapid.  Leading pharmaceutical and biotechnology companies worldwide are using Covaris instruments for RNA extraction, Compound Dissolution, Drug Metabolism tissue extraction, and much more. Information about Covaris is available at https://www.covaris.com.

©Copyright 2007. Covaris, Inc. All rights reserved.
Covaris, TissueTube, CryoPrep™, Acoustics by Covaris, and Adaptive Focused Acoustics are trademarks of Covaris, Inc. in the U.S. and/or certain other countries.

Contact:
Covaris, Inc.
Jim Laugharn, President & CEO
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
Tel: +1 781-932-3959
Fax: +1 781-932-8705
e-mail: info@covaris.com
web: www.covaris.com

Covaris Moves to Expanded Offices in Woburn, Massachusetts, USA

WOBURN, MA—February 1, 2006—Covaris, Inc. a privately held company founded in 1999 to develop instrument systems based on its patented, proprietary, biophysical technology platform, today announced its move to an expanded corporate headquarters in Woburn, Massachusetts., just outside of Boston.

“The continued acceptance of our technology by established pharmaceutical and biotechnology companies requires an expanded operation to support the sustained growth the company has been experiencing,” said James Laugharn, President, Covaris. “We are pleased to be able to provide an improved level of service and support to our existing customer base that the additional space will grant us. This will also enable us to respond to an escalating acceptance of our technology and products in the marketplace.”

Woburn continues to be an invaluable location for our company as it is both near our key suppliers and is readily accessible to one of our major customer market segments, namely the pharmaceutical and biotechnology community of the greater metropolitan Boston area.

About Covaris:
Covaris, Inc. is a privately held company founded in 1999 to develop instrument systems based on its proprietary, patent-pending, biophysical technology platform. The technology is based on focused acoustic energy and applications of shock wave physics for advanced and high-throughput applications in biology and medicine.

Contact:
Covaris, Inc.
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
Tel: +1 781-932-3959
Fax: +1 781-932-8705
e-mail: info@covaris.com